Trial Profile
Safety and efficacy in patients with Inflammatory bowel disease (Crohn's disease and Ulcerative colitis) switched from Infliximab innovator to Infliximab biosimilar: a prospective, cohort, observational, multicenter study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2017 New trial record
- 05 Dec 2017 Results assessing safety and efficacy published in the Alimentary Pharmacology and Therapeutics.